Royalty Pharma Retained Earnings (Accumulated Deficit) 2019-2024 | RPRX
Royalty Pharma retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $2.765B, a 29.51% increase year-over-year.
- Royalty Pharma retained earnings (accumulated deficit) for 2023 were $2.518B, a 28.14% increase from 2022.
- Royalty Pharma retained earnings (accumulated deficit) for 2022 were $1.965B, a 12.88% decline from 2021.
- Royalty Pharma retained earnings (accumulated deficit) for 2021 were $2.255B, a 17.42% increase from 2020.